Emjard™ M XR 25/1000 mg is an extended-release oral tablet produced by Square Pharmaceuticals PLC, Bangladesh. It combines two antidiabetic agents: Empagliflozin 25 mg, a Sodium-glucose co-transporter 2 (SGLT2) inhibitor, and Metformin Hydrochloride 1000 mg, a biguanide. This combination is used to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate.